All Wales Medicines Strategy Group

Grŵp Strategaeth Meddyginiaethau Cymru Gyfan

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA383)

NICE GUIDANCE ISSUED FEBRUARY 2016

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

Final Appraisal Recommendation

Advice No: 1513 – June 2013

Adalimumab (Humira®) 40 mg prefilled pen or 40 mg prefilled syringe

Submission by AbbVie Ltd

Recommendation of AWMSG

Adalimumab (Humira®) is recommended for use within NHS Wales for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of ankylosing spondylitis but with objective signs of inflammation by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have had an inadequate response to, or are intolerant to non steroidal anti-inflammatory drugs (NSAIDs).

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1381), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation was ratified by the Minister for Health and Social Services in July 2013 and will be considered for review in July 2016.

NICE accredited

www.nice.org.uk/accreditation

NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.